ea0063gp155 | Cushing's | ECE2019
Kassi Eva
, Angelousi Anna
, Asonitis Nikos
, Petychaki Foteini
, Diamantopoulos Panayiotis
, Anastasopoulou Amalia
, Benopoulou Olga
, Gogas Helen
Introduction: Immune-check point inhibitors (ICPis) has been shown to significantly improve survival in patients with advanced melanoma. Immune-related endocrinopathies (irEs) and in particular hypophysitis and thyroid dysfunction have been well described with an incidence varying from 917% and 3.813.2% respectively.Methods: This is a retrospective analysis of irEs in 325 (190 men) patients with melanoma receiving ICPis (PD-1/PDL-1 or CTLA-4 ...